Lalistat 2是一种溶酶体酸性脂肪酶（LAL）抑制剂，IC50值为152nM。
Cas No.:1234569-09-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Lalistat 2 is an inhibitor of lysosomal acid lipase (LAL), with an IC50 value of 152nM[1]. Lalistat 2, by targeting and inhibiting LAL, will disrupt the function of lysosomes and promote the formation of the pro-inflammatory adipose tissue macrophage (ATM) phenotype[2]. Lalistat 2 has been widely used to specifically measure LAL activity in human blood samples and cells [3].
In vitro, Lalistat 2 treatment at 0.1μM for 4 days led to lipid accumulation in proliferating C2C12 cells, with significant increases in triglyceride and total cholesterol levels[4]. Treatment with 100μM of Lalistat 2 for 7 days led to alterations in the lipid metabolism of mouse bone marrow stromal cells (BMSCs) and impaired cell differentiation[5]. Lalistat 2 treatment (30μΜ; 24h) inhibited the lipase of triglycerides and hormone-sensitive lipase in COS-7 cells[6]. Treatment with 10μM of Lalistat 2 for 6 hours reduced the release of lipid mediators in peritoneal macrophages[7].
References:
[1] Rosenbaum A I, Cosner C C, Mariani C J, et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann− Pick type C disease therapeutics[J]. Journal of medicinal chemistry, 2010, 53(14): 5281-5289.
[2] Wehr R, Lindhorst A, Arndt L, et al. Lysosomal exocytosis by macrophages as a druggable mechanism for anti-inflammatory clearance of dead adipocytes in adipose tissue[J]. Cell Death & Disease, 2025.
[3] Hamilton J, Jones I, Srivastava R, et al. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2[J]. Clinica chimica acta, 2012, 413(15-16): 1207-1210.
[4] Akhmetshina A, Schooltink L, Amor M, et al. Loss or inhibition of lysosomal acid lipase in vitro leads to cholesteryl ester accumulation without affecting muscle formation or mitochondrial function[J]. BBA advances, 2025, 7: 100135.
[5] Helderman R C, Whitney D G, Duta-Mare M, et al. Loss of function of lysosomal acid lipase (LAL) profoundly impacts osteoblastogenesis and increases fracture risk in humans[J]. Bone, 2021, 148: 115946.
[6] Bradić I, Kuentzel K B, Honeder S, et al. Off-target effects of the lysosomal acid lipase inhibitors Lalistat-1 and Lalistat-2 on neutral lipid hydrolases[J]. Molecular Metabolism, 2022, 61: 101510.
[7] Schlager S, Vujic N, Korbelius M, et al. Lysosomal lipid hydrolysis provides substrates for lipid mediator synthesis in murine macrophages[J]. Oncotarget, 2017, 8(25): 40037.
Lalistat 2是一种溶酶体酸性脂肪酶（LAL）抑制剂，IC50值为152nM[1]。Lalistat 2通过靶向并抑制LAL，将破坏溶酶体功能并促进促炎性脂肪组织巨噬细胞（ATM）表型的形成[2]。Lalistat 2已被广泛用于特异性测定人血液样本和细胞中的LAL活性[3]。
在体外，使用0.1µM的Lalistat 2处理4天，导致增殖的C2C12细胞中脂质积累，甘油三酯和总胆固醇水平显著增加[4]。使用100µM的Lalistat 2处理7天，导致小鼠骨髓基质细胞（BMSCs）的脂质代谢改变并损害细胞分化[5]。Lalistat 2处理（30µM；24小时）抑制了COS-7细胞中的甘油三酯脂肪酶和激素敏感性脂肪酶[6]。使用10µM的Lalistat 2处理6小时，减少了腹腔巨噬细胞中脂质介质的释放[7]。
| Cell experiment [1]: | |
Cell lines | C2C12 cells |
Preparation Method | The C2C12 cells were cultured in high-glucose DMEM medium, supplemented with 10% low-fat serum (LPDS) and 1% penicillin/streptomycin, and were incubated in a 37°C, 5% CO2 incubator. The cells were cultured with 0.1μM of Lalistat 2 for 4 days, and then the lipid levels within the cells were analyzed. |
Reaction Conditions | 0.1µM; 4 days |
Applications | Lalistat 2 treatment resulted in lipid accumulation in the C2C12 cells. |
References: | |
| Cas No. | 1234569-09-5 | SDF | |
| Canonical SMILES | O=C(N1CCCCC1)OC2=NSN=C2N3CCCCC3 | ||
| 分子式 | C13H20N4O2S | 分子量 | 296.4 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 20 mg/ml,Ethanol:PBS(pH 7.2) (1:5): 0.16 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3738 mL | 16.8691 mL | 33.7382 mL |
| 5 mM | 674.8 μL | 3.3738 mL | 6.7476 mL |
| 10 mM | 337.4 μL | 1.6869 mL | 3.3738 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet